[Effects of amrinone, a new non-digitalic positive inotropic agent, on the efficiency and coronary circulation of the heart].
It has been reported recently that 5-amino-34,4'-bipyridine-6(1H)-one is a new positive inotropic agent that appears to offer significant advantages over the cardiac glycosides. The effects of this agent were studied in a modified heart-lung preparation which allows the measurement of coronary flow and oxygen consumption in addition to a controlled study of cardiac contractility. In two models of cardiac insufficiency the administration of 5 mg amrinone caused a marked increase in cardiac output and a considerable decrease in left atrial pressure with complete reversal of the failure. In addition, the drug produces a 78% increase in coronary flow. Amrinone produces in these preparations a proportionally larger increase in cardiac output than in oxygen consumption, thus this agent increases cardiac efficiency. These results suggest that this new compound could be very useful in the treatment of cardiac insufficiency in congestive heart failure.
D000631:Aminopyridines / Q000494:pharmacology*; D000676:Amrinone; D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D003326:Coronary Circulation / Q000187:drug effects*; D004285:Dogs; D005260:Female; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000503:physiopathology; D006334:Heart Function Tests; D006439:Hemodynamics / Q000187:drug effects*; D008297:Male; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects
D000631:Aminopyridines; D002316:Cardiotonic Agents; D000676:Amrinone
Effectos del amrinone, un nuevo agente inotrópico positivo no digitálico, sobre la eficiencia y el flujo coronario del corazón.